| Literature DB >> 35070291 |
Setthasorn Zhi Yang Ooi1, Rosaline de Koning1, Abdullah Egiz1, David Ulrich Dalle1, Moussa Denou1, Marvin Richie Dongmo Tsopmene1, Mehdi Khan1, Régis Takoukam1, Jay Kotecha1, Dawin Sichimba1, Yao Christian Hugues Dokponou1, Ulrick Sidney Kanmounye1, Nourou Dine Adeniran Bankole1.
Abstract
INTRODUCTION: Despite recent advancements in the management of low-grade gliomas (LGGs), there is a paucity in the data within the African landscape. We aim to evaluate the epidemiology, management, and outcomes of LGGs in Africa.Entities:
Keywords: Africa; Epidemiology; Low-grade glioma; Management; Outcomes
Year: 2022 PMID: 35070291 PMCID: PMC8762355 DOI: 10.1016/j.amsu.2022.103246
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Fig. 1PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) flow diagram for study selection.
Characteristics of the low-grade glioma in Africa studies.
| Characteristic | Frequency (Percentage) |
|---|---|
| Publication year | |
| 1980–1989 | 1 (4.0) |
| 2000–2009 | 2 (8.0) |
| 2010–2019 | 20 (80.0) |
| 2020 | 2 (8.0) |
| Study setting | |
| Nigeria | 8 (32.0) |
| Egypt | 5 (20.0) |
| Morocco | 4 (16.0) |
| Tunisia | 3 (12.0) |
| Uganda | 2 (8.0) |
| Cameroon | 1 (4.0) |
| Ghana | 1 (4.0) |
| Kenya | 1 (4.0) |
| Study design | |
| Cross-sectional | 16 (64.0) |
| Case report | 5 (20.0) |
| Case series | 3 (12.0) |
| Qualitative | 1 (4.0) |
Precise location of LGGs in African patients.
| Location | Value | Lower limit 95% CI | Upper limit 95% CI |
|---|---|---|---|
| Cerebellar | 44.0% | 39.5% | 48.5% |
| Brainstem | 27.6% | 23.6% | 31.5% |
| Frontal lobe | 13.2% | 10.1% | 16.3% |
| Parietal lobe | 7.0% | 4.7% | 9.3% |
| Temporal lobe | 6.2% | 4.0% | 8.4% |
| Interlobar | 1.6% | 0.4% | 2.7% |
| Occipital lobe | 0.4% | −0.2% | 1.0% |
Fig. 2TreeMap of the histopathology of low-grade gliomas in Africa by type (words at the top left corner) and showing their prevalence (first number) and corresponding 95% confidence intervals (second and third numbers represent lower and upper limits respectively). PGNT - Papillary glioneuronal tumour, PNET - Primitive neuro-ectodermal tumour, PXA - Pleomorphic xanthoastrocytoma, SEGA - Subependymal giant cell astrocytoma.